Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
2.400
-0.080 (-3.23%)
At close: Jul 3, 2025, 1:00 PM
2.390
-0.010 (-0.42%)
After-hours: Jul 3, 2025, 2:29 PM EDT
Phio Pharmaceuticals Employees
Phio Pharmaceuticals had 5 employees as of December 31, 2024. The number of employees decreased by 4 or -44.44% compared to the previous year.
Employees
5
Change (1Y)
-4
Growth (1Y)
-44.44%
Revenue / Employee
n/a
Profits / Employee
-$1,353,000
Market Cap
11.52M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PHIO News
- 8 days ago - Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort - Newsfile Corp
- 9 days ago - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile Corp
- 27 days ago - Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio - Newsfile Corp
- 6 weeks ago - Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference - Newsfile Corp
- 7 weeks ago - Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Newsfile Corp
- 2 months ago - Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial - Newsfile Corp
- 3 months ago - Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort - Newsfile Corp
- 3 months ago - Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894 - Newsfile Corp